NCT05432258 is a NA clinical trial of Bulk-fill composite resin in Composite Resin, sponsored by Izmir Katip Celebi University.

Who is sponsoring NCT05432258?

NCT05432258 is sponsored by Izmir Katip Celebi University.

What drugs are being tested in NCT05432258?

Interventions in NCT05432258: Bulk-fill composite resin, Nano-fill composite resin.

What condition does NCT05432258 study?

NCT05432258 studies Composite Resin, Dental Caries in Children.

Is NCT05432258 still recruiting?

NCT05432258 is currently completed. Last updated 2 October 2023.

Last reviewed 2023-10-02 · How we verify

NCT05432258

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nano-Hybrid vs Bulk-Fill Resin Composites

Completed NA Last updated 2 October 2023

What this trial tests

NA trial testing Bulk-fill composite resin in Composite Resin in 89 participants. Completed in 26 July 2022.

Timeline

15 June 2020

Primary endpoint
26 July 2022

26 July 2022

Quick facts

Lead sponsor	Izmir Katip Celebi University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	89
Start date	15 June 2020
Primary completion	26 July 2022
Estimated completion	26 July 2022
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Bulk-fill composite resin
Nano-fill composite resin

Conditions studied

Composite Resin — all drugs for Composite Resin →
Dental Caries in Children — all drugs for Dental Caries in Children →

Sponsor

Izmir Katip Celebi University

Who can join

Adults 6 to 12, any sex, with Composite Resin or Dental Caries in Children. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to compare the 2-year clinical performance of bulk-fill composites, which can be applied as a single layer, and the nano-hybrid filled composite resins, which are frequently used in clinical routine, in children in a split-mouth design. This study was conducted on 89 patients aged 6-12 years who had caries on bilateral mandibular first molars. Our study has a randomized, cross-controlled, and double-blind design. In split-mouth design, restorations of mandibular permanent molars completed with nano-hybrid ORMOCER based bulk-fill filling material Admira Fusion x-tra (Voco GmbH, Cuxhaven, Germany) and nano-hybrid composite Grandio (Voco , Cuxhaven, Germany). Futurabond U single dose (Voco, Cuxhaven, Germany) universal adhesive was used for all restorations, in the selective enamel etching mode. The clinical success of the restorations will be evaluated at 6, 12 and 24-month controls. Evaluations has been made by two physicians other than the one who did the restoration, who do not know which restorative material was applied to which tooth.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Two-year evaluation of a nano-hybrid and a bulk-fill resin composite: a randomized, double-blind split-mouth clinical study.
Çağırır Dindaroğlu F, Yılmaz E. · · 2024 · cited 7× · PMID 38467942 · DOI 10.1007/s00784-024-05592-8

Verify or expand the search:

Other Izmir Katip Celebi University trials

Trials by the same sponsor.

NCT07460479 — Pilot Study of an Extended CBT Group Intervention for Intolerance of Uncertainty · NA · recruiting
NCT07453277 — Blood-Based Molecular Clock Biomarkers Predict Acute Ischemic Stroke Onset: A Prospective Observational Study · active not recruiting
NCT07341646 — Effect of Cuff Pressure Assessment Methods on Postoperative Complications in Breast Surgery · NA · not yet recruiting
NCT07304661 — Comparison of PPV and LVOT VTI During Passive Leg Raising to Predict Fluid Responsiveness · not yet recruiting
NCT07304648 — Role of End-Tidal CO2 During Passive Leg Raising to Predict Fluid Responsiveness in ICU · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05432258 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Izmir Katip Celebi University
Last refreshed: 2 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05432258.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing